Argenx reports positive Phase 3 autoimmune myositis trial results

On November 7, argenx reported Phase 3 ALKIVIA results showing a 15.4-point advantage over placebo in Week 52 Total Improvement Score for the combined IMNM and DM population. The IMNM subgroup posted a 14.8-point advantage, while the DM subgroup showed a 14.5-point advantage that was not statistically significant. Argenx plans to seek FDA review of efgartigimod for IMNM before 2026 ends, citing the drug's Breakthrough Therapy Designation.

The results give argenx a regulatory path for efgartigimod in IMNM, where the company says there are no approved therapies. The DM result was clinically meaningful but did not meet statistical significance, leaving the evidence less conclusive for that subgroup.

  • 1The combined IMNM and DM population showed a 15.4-point greater Week 52 improvement in mean TIS versus placebo, with results of 48.0 versus 32.6 and p=0.0011.
  • 2In IMNM, efgartigimod produced a 14.8-point greater mean TIS improvement than placebo at Week 52, with results of 45.1 versus 30.2 and p=0.0048.
  • 3The DM subgroup recorded a 14.5-point greater mean TIS improvement versus placebo at Week 52, with results of 51.5 versus 37.0 and p=0.1093.
  • 4The ALKIVIA trial randomized 265 patients, and 175 patients received treatment in its Phase 3 portion.
  • 5Argenx plans to submit an sBLA to the FDA for efgartigimod in IMNM before the end of 2026.

Sources